Clinician Perspectives on Genetic Testing for FTDPlease enable JavaScript in your browser to complete this form.Please enable JavaScript in your browser to complete this form.Please complete this survey so that we can better understand what the clinician community values most about genetic testing for frontotemporal degeneration (FTD) and related conditions. Your responses may assist in the development of a future sponsored testing program (genetic counseling and testing available at no cost to the patient with the costs covered by an organization). You may skip any question you do not wish to answer. Approved October 13th, 2026 North Star Review Board Research Title: Survey of Clinician Perspectives on Genetic Testing for FTD Protocol #: NB400226 Researcher: Carrie Milliard, MS, CGC, CCRP, FTD Disorders Registry, LLC Contact Information: 415-646-4456 ext 105, cmilliard@ftdregistry.org Research Sponsor: FTD Disorders Registry, LLC Purpose, Procedure, and Duration: Researchers at the FTD Disorders Registry are conducting a survey to understand the perspectives of clinicians about genetic testing for FTD, as well as sponsored genetic testing programs that may be available at no cost to the patient with the cost covered by an organization. The survey will take approximately 15 minutes. Benefits: You may not benefit personally from being in this study, but your answers could inform the development of future sponsored genetic tests for FTD and help us better understand what matters most to clinicians when choosing a genetic test. Risks: We do not anticipate any questions in this survey to cause discomfort, but you can skip any question you don’t want to answer. You can also stop the survey at any time. We will make every effort to safeguard your data. However, we cannot guarantee the security of data obtained via the internet. Alternative Opportunities: We know of no alternative except not to participate in our study. Privacy and Future Use: Your responses to the research survey are anonymous. That means we won’t know which responses are yours. We won’t collect names, internet addresses, email addresses, or any other identifiable information. We may use your anonymous responses in future research or share them with other researchers. Complaints or Concerns: If you have questions, concerns, or complaints about the research study and/or your participation in the research study, please contact Carrie Milliard, MS, CGC, CCRP, Director at FTD Disorders Registry, LLC at cmilliard@ftdregistry.org This research is being overseen by North Star Review Board. An IRB is a group of people who perform independent reviews of research studies. You may contact North Star Review Board at 877-673-8439 (toll free) or info@northstarreviewboard.org if: You have questions, concerns, or complaints that are not being answered by the research team. You are not getting answers from the research team. You cannot reach the research team. You want to talk to someone else about the research study. You have questions about your rights as a research subject. Thank you for taking the time to consider our study. You do not have to participate in our study, but we hope you will. By proceeding to complete and submit this survey, you are confirming that you have read and understood the information provided in this consent document, and you voluntarily agree to participate in this research study. I consentWhat type of healthcare provider or researcher are you?Physician (MD, DO, or equivalent)Genetic CounselorPsychologistNurse PractitionerPhysician Associate/Assistant (PA)Other (please specify)Which best describes your primary area of clinical practice?Adult general geneticsGeneral/medical genetics (all ages)Adult neurodegenerative disordersNeuromuscular disordersAdult neurologyCognitive disordersGeriatricsPsychology or NeuropsychologyPsychiatryPrimary careOther (please specify)Which best describes your primary practice setting? Private PracticeAcademic Medical Center or Teaching HospitalCommunity or County HospitalDiagnostic, Academic, or Commercial LaboratoryIndustry/Biotechnology/Pharmaceutical CompanyPublic Health AgencyTelehealth PracticeOther (please specify)Select all that applyPractice Setting - OtherHow would you describe your familiarity with FTD?Very familiarSomewhat familiarNot familiarHow familiar are you with genetic causes of FTD?Very familiarSomewhat familiarNot familiarHave you discussed genetic counseling or genetic testing with a person(s) diagnosed with FTD within the last year?YesNoUnsureHave you ordered genetic testing for FTD within the last year?YesNoUnsureFor the following questions, a sponsored testing program refers to genetic counseling and testing available to a patient at no cost, with the funding provided by a sponsoring organization. I would refer patients diagnosed with FTD to a sponsored genetic testing program (or order it myself) if one were availableStrongly agreeAgreeNeutralDisagreeStrongly disagreeUnsureIn addition to genetic causes of FTD, would you want a sponsored genetic test for FTD to include genes related to any of the following conditions?ALSAlzheimer's disease (except APOE)APOE Alzheimer's risk allelesOther dementias (e.g. Lewy Body)Parkinson's diseaseOther neurodegenerative disorders or clinical conditions that may mimic FTD or ALSSomething elseNone of theseSelect all that applyOther Condition to include *Clinical genetic testing laboratories may report a pathogenic C9orf72 expansion as ≥30 repeats. For your clinical practice, how important would it be for a lab to report a more precise size of a repeat expansion allele in C9orf72 for individuals with FTD or ALS?Very importantSomewhat importantNeutralSomewhat unimportantNot important at allFor your clinical practice, how important would it be for a lab to report the exact repeat size of a normal allele in C9orf72 for individuals with FTD or ALS?Very importantSomewhat importantNeutralSomewhat unimportantNot important at allTo what extent should a sponsored testing panel for FTD include genes with preliminary or limited evidence for association with FTD or ALS?Include any gene with preliminary or limited evidenceThese genes could be considered on a case-by-case basisNot at all: only include genes with moderate, strong, or definitive evidenceUnsure For the following set of questions, please consider a typical referral for FTD. I would prefer a genetic test for FTD that maximizes gene coverage by including as many relevant genes as possible.Strongly AgreeAgreeNeutralDisagreeStrongly DisagreeUnsureI would prefer a genetic test for FTD that is confined in scope to the most relevant genes (such as C9orf72, GRN, MAPT, VCP, TARDBP, TBK1, FUS, CHMP2B)Strongly AgreeAgreeNeutralDisagreeStrongly DisagreeUnsureAt a minimum, a sponsored testing program for FTD could include the primary 3 genes associated with genetic FTD (C9orf72, GRN, MAPT) as well as any other gene with a Definitive gene-disease association with FTD or ALS according to ClinGen (Welcome to ClinGen) curation. Are there other genes you would desire on a sponsored test for FTD? Please list any genes above and provide any rationale or supporting comments. As an example: TMEM106B – modifies penetrance of GRN-FTD; CSF1R – causes condition that may mimic FTD.How concerned are you about patients receiving a report containing variants of uncertain significance (VUS) through a sponsored FTD testing program?Very concernedSomewhat concernedNot concernedUnsureIf you were ordering a customized panel for FTD, would you prefer a genome backbone/platform over an exome backbone/platform? YesNoUnsureIf you were ordering genetic testing for FTD, would you prefer genome sequencing over a customized multi-gene panel targeted at genetic causes of FTD and related conditions:YesNoUnsurePlease provide any comments you may have about utilizing a sponsored testing program for FTD. You may leave this blank if you have no comments. Submit